What is this survey?
In 2022, the Endocrine Society and the global ‘Working Group for Renaming Diabetes Insipidus’ recommended a name change from diabetes insipidus (CDI) to Arginine Vasopressin Deficiency (AVP deficiency, AVP-D) in order to better reflect the condition’s pathophysiology and avoid confusion with diabetes mellitus.
But has this change been widely adopted in clinical practice? Is there still confusion between the two terms in 2025? Do healthcare professionals and patients understand how to safely manage AVP-D and desmopressin (and avoid complications like hyponatremia and hypernatremia)?
🌎 This global survey aims to find out!
Researchers wish to gather insights from clinicians on how AVP deficiency is understood, diagnosed, and managed across specialties (both endocrine and non-endocrine). If you are a healthcare professional, your participation will help improve patient education and clinical practices for this rare condition.
The survey takes just a few minutes, and your responses are anonymous. You can reply to the survey here: https://feedback.surveylab.com/92c/HCP/AVP-D/SURVEY/
Not a clinician but want to get involved? You can share this survey with your healthcare providers (endocrinologists, GPs, nurses, pharmacists) and ask them to submit a response! You can share the URL link to this page or ask them to scan the QR code below.
Scan or share this QR code to access the survey.